Flortaucipir (18F)

From WikiMD's Wellness Encyclopedia

(Redirected from Tauvid)

What is Flortaucipir (18F)?[edit | edit source]

Flortaucipir.png

What are the uses of this medicine?[edit | edit source]

How does this medicine work?[edit | edit source]

  • Flortaucipir F 18 binds to aggregated tau protein.
  • In the brains of patients with AD, tau aggregates combine to form NFTs, one of two components required for the neuropathological diagnosis of AD.

Who Should Not Use this medicine ?[edit | edit source]

This medicine cannot be used in patients if:

Is this medicine FDA approved?[edit | edit source]

  • It was approved for use in the United States in 2020.

How should this medicine be used?[edit | edit source]

  • TAUVID is a radioactive drug.
  • Only authorized persons qualified by training and experience should receive, use, and administer TAUVID.
  • Handle TAUVID with appropriate safety measures to minimize radiation exposure during administration .
  • Use waterproof gloves and effective shielding, including syringe shields, when preparing and handling TAUVID.

Recommended Dose

  • The recommended amount of radioactivity to be administered for PET imaging is 370 MBq (10 mCi), administered as an intravenous bolus injection in a total volume of 10 mL or less.
  • Initiate imaging approximately 80 minutes after drug administration.

Administration

  • Assessment of pregnancy status is recommended in females of reproductive potential before administering TAUVID.
  • Use aseptic technique and radiation shielding during the preparation and administration of TAUVID.
  • Visually inspect the radiopharmaceutical solution prior to administration. Do not use it if it contains particulate matter or if it is discolored (TAUVID is a clear, colorless solution).
  • TAUVID may be diluted aseptically with 0.9% Sodium Chloride Injection to a maximum dilution of 1:5 by the end-user. Diluted product should be used within 3 hours of dilution and prior to product expiry.
  • Assay the dose in a suitable dose calibrator prior to administration.

What are the dosage forms and brand names of this medicine?[edit | edit source]

This medicine is available in fallowing doasage form:

  • As Injection: 300 MBq/mL to 1,900 MBq/mL (8.1 mCi/mL to 51 mCi/mL) of flortaucipir F 18 injection in a multiple-dose vial.

This medicine is available in fallowing brand namesː

  • TAUVID

What side effects can this medication cause?[edit | edit source]

Common possible side effects of this medicine include:

  • headache
  • injection site pain
  • increased blood pressure

What special precautions should I follow?[edit | edit source]

  • Ensure safe drug handling to protect patients and health care workers from unintentional radiation exposure.
  • The safety and effectiveness of TAUVID have not been established for patients being evaluated for Chronic Traumatic Encephalopathy.
  • Consider additional evaluation to confirm the absence of AD pathology in patients with a negative TAUVID scan.

What to do in case of emergency/overdose?[edit | edit source]

  • In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.

Can this medicine be used in pregnancy?[edit | edit source]

  • TAUVID, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of radiation dose.
  • Advise a pregnant woman of the potential risks of fetal exposure to radiation doses with administration of TAUVID.
  • TAUVID is not likely to be used in females of reproductive age.

Can this medicine be used in children?[edit | edit source]

  • The safety and effectiveness of TAUVID in pediatric patients have not been established.

What should I know about storage and disposal of this medication?[edit | edit source]

  • Store TAUVID at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) .
  • TAUVID does not contain a preservative.
  • Store TAUVID upright in a shielding container.
  • The expiration date and time are provided on the container label.
  • Use TAUVID within the labeled expiration.

Handling

  • This preparation is approved for use by persons under license by the Nuclear Regulatory Commission or the relevant regulatory authority of an Agreement State.


Flortaucipir (18F) Resources

Contributors: Deepika vegiraju